NRGGU013
OPEN TO ACCRUAL
Phase III SBRT vs Conventional or Moderate Hypofractionation for High-Risk Prostate Cancer
NWU22-12-01
OPEN TO ACCRUAL
PH2 Placebo-Controlled Trial of Urolithin a in Prostate Cancer Undergoing Radical Prostatectomy
S2312
OPEN TO ACCRUAL
Phase III Study of Cabazitaxel w/ or w/o Carboplatin in MCRPC Patients
UW22067
OPEN TO ACCRUAL
PET/CT Characterization of Treatment Resistance of AR-targeted therapies in mCRPC
UW24097
OPEN TO ACCRUAL
Phase II MDRT for oligometastatic prostate cancer treated with ADT in the STAMPEDE trial (METANOVA).
UW24109
OPEN TO ACCRUAL
Ph1: Safety+Tolerability of Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS)
UW25025
OPEN TO ACCRUAL
P1: Pilot trial of pTVG-HP+Nivo+targeted ablation of resistant lesions in Non-Castrate RecurrentOMPC
UW25057
OPEN TO ACCRUAL
Ph 1/1b Open-Label, Study of ORIC-944 as a Single Agent or in Combo with AR Pathway Inhibitor in mPC
UW25078
OPEN TO ACCRUAL
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer
UW26015
OPEN TO ACCRUAL
Exact Sciences urine collection study